EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients

Update Il y a 4 ans
Reference: NCT00448305

Woman Man

Extract

The purpose of this study is to assess the efficacy, safety and tolerability of a therapy with EndoTAG-1 + paclitaxel in combination and EndoTAG-1 alone as a rescue therapy for patients with relapsed or metastatic triple receptor negative breast cancer (a special subgroup of breast cancer).


Inclusion criteria

  • Breast Neoplasms


Links